Pages that link to "Q28296777"
Jump to navigation
Jump to search
The following pages link to The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice (Q28296777):
Displaying 50 items.
- The pharmacological landscape and therapeutic potential of serine hydrolases (Q26995817) (← links)
- Structure-guided inhibitor design for human FAAH by interspecies active site conversion (Q27651822) (← links)
- Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain (Q27655121) (← links)
- Crystal Structure of Fatty Acid Amide Hydrolase Bound to the Carbamate Inhibitor URB597: Discovery of a Deacylating Water Molecule and Insight into Enzyme Inactivation (Q27661834) (← links)
- Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice (Q28262282) (← links)
- The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review (Q28267813) (← links)
- Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders (Q28285103) (← links)
- Enzymatic pathways that regulate endocannabinoid signaling in the nervous system (Q28390932) (← links)
- Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats (Q28548007) (← links)
- Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain (Q28575056) (← links)
- Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. (Q30492114) (← links)
- The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model (Q30733453) (← links)
- Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain (Q33560467) (← links)
- Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside (Q34019573) (← links)
- Assessment of the pharmacology and tolerability of PF‐04457845, an irreversible inhibitor of fatty acid amide hydrolase‐1, in healthy subjects (Q34029257) (← links)
- Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. (Q34101852) (← links)
- Endocannabinoid Overload: Fig. 1 (Q34144131) (← links)
- Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain (Q34179408) (← links)
- Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. (Q34231719) (← links)
- Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models (Q34390806) (← links)
- β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine (Q34423074) (← links)
- A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo (Q34467166) (← links)
- Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea. (Q34478780) (← links)
- A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects (Q34479599) (← links)
- The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects (Q34496064) (← links)
- The endocannabinoid system and pain (Q34612917) (← links)
- Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms (Q34801735) (← links)
- Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey (Q34953319) (← links)
- Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice (Q35189004) (← links)
- Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors (Q35202878) (← links)
- Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice (Q35223920) (← links)
- Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors (Q35532072) (← links)
- A catalytically silent FAAH-1 variant drives anandamide transport in neurons (Q35633097) (← links)
- Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. (Q35678770) (← links)
- Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy (Q35689152) (← links)
- Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy (Q36006338) (← links)
- Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice (Q36057960) (← links)
- The fatty acid amide hydrolase (FAAH) inhibitor PF‐3845 acts in the nervous system to reverse LPS‐induced tactile allodynia in mice (Q36176531) (← links)
- Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain (Q36223310) (← links)
- Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability (Q36455289) (← links)
- Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics follo (Q36476481) (← links)
- Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor (Q36485064) (← links)
- Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model (Q36744213) (← links)
- A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation (Q36823364) (← links)
- Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects (Q36852591) (← links)
- Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain (Q36912778) (← links)
- Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions (Q37082114) (← links)
- Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. (Q37098652) (← links)
- Targeting the endocannabinoid system: to enhance or reduce? (Q37150745) (← links)
- Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception (Q37162136) (← links)